SCHEMBL5203586

SCHEMBL5203586

COc1cc(I)cc(OC)c1OCC(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
USP2 O75604 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
THRB P10828 1/20 0.40
G6PD P11413 1/20 0.40
ALOX15 P16050 1/20 0.40
CASP1 P29466 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SCN9A Q15858 1/20 0.36
HTR2A P28223 3/20 0.35
HTR2C P28335 2/20 0.35
HTR2B P41595 1/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14835309 0.81 ALDH1A1 (0.47) MAPTALDH1A1KDM4EL3MBTL1CYP3A4
Hydrochloric Acid SCHEMBL5205490 0.80 MAPT (0.52) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL29896392 0.77 MEN1 (0.37) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL6339479 0.77 MAPT (0.37) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5208819 0.76 HTR2A (0.56) MAPTMEN1KMT2AKDM4EHTR2A
SCHEMBL5205202 0.76 TPMT (0.54) ALDH1A1MEN1KMT2AHSD17B10L3MBTL1
SCHEMBL5203497 0.75 CYP2C9 (0.35) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5204737 0.75 TSHR (0.51) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL29176987 0.75 MAPT (0.39) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5208622 0.73 TNFRSF1A (0.47) MAPTALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1403251-B1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE KOWA CO (JP) 2007-07-18 EP disclosed
US-6890940-B2 Bis(2-aryl-5-pyridyl) derivatives KOWA CO., LTD. (JP) 2005-05-10 US disclosed
EP-1403251-A1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE Kowa Co., Ltd. (JP) 2004-03-31 EP disclosed
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy IGLV6-57, IL5, IGSF11 MAPT 1013/4885ALDH1A1 2780/4885MEN1 3218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.